Strategic funding Leverage NIH grant traction and upcoming $2.9M award to position Scanogen as a funded innovator in rapid, culture-free bloodstream infection diagnostics, targeting hospitals and clinical labs seeking validated, grant-supported solutions.

Clinical focus Target point-of-care and bloodstream infection diagnostic segments where Scanogen’s SMOLT technology can offer rapid, sample-to-answer results, appealing to urgent-care settings, ICU workflows, and infectious disease programs.

SMOLT advantage Highlight ultra-sensitive, single-molecule detection as a differentiator for biomolecular readouts in body fluids, enabling attractive value propositions for faster decision-making and reduced hospital stay costs.

Growth readiness With a small but skilled team and external grants, pursue partnerships and co-development deals with larger diagnostics players to scale regulatory clearance, manufacturing, and commercialization efforts.

Market positioning Position Scanogen among mid-size competitors with scalable revenue potential by aligning with established labs and hospital systems while leveraging NIH funding credibility to differentiate from larger incumbents.